Point-of-Care Test for Recurrent Bladder Cancer Available

Publication
Article
OncologyONCOLOGY Vol 23 No 3
Volume 23
Issue 3

Polymedco, Inc, announced the availability of the BTA Stat test-a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor–associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine.

Polymedco, Inc, announced the availability of the BTA Stat test-a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor–associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine.

The specificity of the BTA Stat test was 93% to 95% in patients with nongenitourinary diseases and cancers and healthy individuals tested in a multicenter study. The test has a sensitivity that is considerably higher than voided urine cytology, enabling detection of recurrent early-stage and low-grade cancers that cytology often misses. Requiring only three drops of urine, the result is delivered in 5 minutes. The appearance of a line in the patient window indicates a positive result. The BTA Stat test requires one voided urine sample with no sample preparation. The test is clinical laboratory improvement amendments (CLIA) waived and also available for prescription home use.

For more information, contact Polymedco at 800-431-2123 or 914- 739-5400, or visit www.polymedco. com/ or www.btastat.com.

Related Videos
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content